554430-67-0

Usage

Uses

Used in Pharmaceutical Research:
1-(2-(4-iodophenoxy)ethyl)pyrrolidine is used as a building block for the synthesis of new drugs, leveraging its unique structure and functional groups to contribute to the development of innovative medicinal compounds.
Used in Chemical Research:
In the field of chemical research, 1-(2-(4-iodophenoxy)ethyl)pyrrolidine serves as a valuable tool, potentially aiding in the development of novel materials or acting as a reagent in organic synthesis processes.
Overall, 1-(2-(4-iodophenoxy)ethyl)pyrrolidine holds promise as a significant contributor to scientific research and development, with applications spanning across pharmaceutical and chemical domains.

Upstream product

• 540-38-5 p-Iodophenol 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 5050-41-9 N-(2-chloroethyl)-pyrrolidine 

Downstream Products

• 690264-03-0 1-[2-(4-trimethylsilanylethynyl-phenoxy)-ethyl]-pyrrolidine 
• 690266-88-7 1-{2-[4-(4-bromo-thiophen-2-ylethynyl)-phenoxy]-ethyl}-pyrrolidine 
• 1427186-49-9 C₁₄H₁₆F₂INO 
• 1427186-52-4 C₁₇H₂₅F₂NOSi 
• 1418146-27-6 C₂₃H₃₀FNOSi 
• 554430-15-8 5-(tert-butyl-dimethyl-silyloxy)-2-(7-(tert-butyl-dimethyl-silyloxy)-4-{hydroxy-[4-(2-pyrroidine-1-yl-ethoxy)-phenyl]-methyl}-2H-chromen-3-yl)-phenol 

Relevant academic research and scientific papers

Synthesis and growth inhibition activity of fluorinated derivatives of tamoxifen

The design and synthesis of 11 fluorinated derivatives of tamoxifen are described. Growth inhibition values (GI50) on human HT-29, M21, MCF7, and MDA-MB-231 tumor cells are also reported. In general, the GI50 values are similar or sl

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

2-PHENYLPYRIDIN-4-YL DERIVATIVES AS ALK5 INHIBITORS

This invention relates to novel 2-phenylpyridin-4-yl heterocyclyl derivatives which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

PYRAZOLE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR

The invention relates to novel pyrazole derivatives of formula (I), which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

PYRIDINYL SUBSTITUTED (1,2,3,)TRIAZOLES AS INHIBITORS OF THE TGF-BETA SIGNALLING PATHWAY

The invention relates to novel triazole derivatives which are inhibitors of the transforming growth factor, ("TGF")-? signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase ("ALK")-5 receptor, m